Andrea Camerini
Overview
Explore the profile of Andrea Camerini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
846
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Mountzios G, De Toma A, Economopoulou P, Friedlaender A, Banini M, Lo Russo G, et al.
Clin Lung Cancer
. 2020 Nov;
22(2):e180-e192.
PMID: 33162330
Background: Real-world data have suggested a detrimental effect of steroid use in patients with advanced non-small-cell lung cancer (NSCLC) receiving immunotherapy. However, previous studies included heterogeneous cohorts of patients receiving...
22.
Metro G, Banna G, Signorelli D, Gili A, Galetta D, Galli G, et al.
J Immunother
. 2020 Sep;
43(9):299-306.
PMID: 32991393
The authors conducted a multicenter retrospective study on the outcome of programmed death-ligand 1 tumor proportion score≥50% advanced non-small cell lung cancer patients treated with first-line pembrolizumab according to the...
23.
Friedlaender A, Metro G, Signorelli D, Gili A, Economopoulou P, Roila F, et al.
Acta Oncol
. 2020 Aug;
59(9):1058-1063.
PMID: 32762415
We retrospectively analysed patients with advanced non-small-cell lung cancer (NSCLC) harbouring high PD-L1 expression (>50%) and treated with front-line pembrolizumab, comparing outcomes of patients with an Eastern Cooperative Oncology Group...
24.
Canale M, Camerini A, Casolo G, Lilli A, Bisceglia I, Parrini I, et al.
Adv Ther
. 2020 May;
37(7):3178-3184.
PMID: 32436027
Introduction: Cardiovascular toxicity of immunotherapy represents an underreported but potentially fatal side effect. A relatively high incidence of pericardial disease has been noticed in patients with non-small cell lung cancer...
25.
Facchinetti F, Mazzaschi G, Barbieri F, Passiglia F, Mazzoni F, Berardi R, et al.
Eur J Cancer
. 2020 Mar;
130:155-167.
PMID: 32220780
Background: Pembrolizumab is the first-line standard of care for advanced non-small cell lung cancer (NSCLC) with a PD-L1 tumour proportion score (TPS) ≥ 50%. Eastern Cooperative Oncology Group performance status...
26.
Metro G, Addeo A, Signorelli D, Gili A, Economopoulou P, Roila F, et al.
J Thorac Dis
. 2020 Feb;
11(12):4972-4981.
PMID: 32030213
Background: In this real-world multicenter study we addressed the activity of post-progression anticancer treatments after first-line pembrolizumab in advanced non-small cell lung cancer (NSCLC) patients with PD-L1 ≥50%. Methods: Clinico-pathological...
27.
Berardi R, Mastroianni C, Lo Russo G, Buosi R, Santini D, Montanino A, et al.
Ther Adv Med Oncol
. 2019 Oct;
11:1758835919877725.
PMID: 31632468
Background: Hyponatremia in cancer patients is often caused by the syndrome of inappropriate antidiuretic hormone secretion (SIADH). The aim of this observational multicenter study was to analyze the medical and...
28.
Canale M, Camerini A, Huqi A, Lilli A, Bisceglia I, Parrini I, et al.
Anticancer Res
. 2019 Oct;
39(10):5741-5745.
PMID: 31570476
Background/aim: Cardiovascular risk factors (CVRFs) predict cardiotoxicity in cancer patients but their role in late cardiac toxicity is less clear. Patients And Methods: This was a retrospective analysis of patients...
29.
Pujol J, Coffy A, Camerini A, Kotsakis A, Mencoboni M, Gusella M, et al.
PLoS One
. 2019 Aug;
14(8):e0220988.
PMID: 31430345
Introduction: Several non-comparative phase II studies have evaluated metronomic oral vinorelbine (MOV) in metastatic non-small cell lung cancer (NSCLC) but the small size of each study limits their conclusions. Purpose:...
30.
Passaro A, Prelaj A, Bonanno L, Tiseo M, Tuzi A, Proto C, et al.
Clin Lung Cancer
. 2018 Dec;
20(2):e186-e194.
PMID: 30563752
Background: Molecular characterization of non-small-cell lung cancer (NSCLC), defined predictive and druggable mutations that greatly modified patient prognoses. The most frequent driver mutations detected in NSCLC are epidermal growth factor...